Compounded semaglutide after the crackdown: what is actually legal in 2026
The shortage is over, the deadlines have passed, and compounded semaglutide is still sold widely. That is not proof it is legal — and not proof it isn't. The truth runs through one word: individualized.
The FDA declared the semaglutide shortage resolved on February 21, 2025. Compounding “essentially a copy” of Wegovy or Ozempic under the shortage exception ended for 503A pharmacies on April 22, 2025 and for 503B outsourcing facilities on May 22, 2025. On April 30, 2026 the FDA proposed excluding semaglutide from the 503B bulks list entirely. What remains legal is narrow: patient-specific 503A compounding with a documented clinical difference, plus a limited safe harbor of four or fewer “essentially a copy” prescriptions per pharmacy per month.
- How the shortage exception opened and closed: The legal foundation of the compounded semaglutide boom was drug-shortage law.
- The April 2026 escalation: On April 30, 2026 the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the roster of bulk drug subs.
- The narrow paths that survive: Compounding law never banned compounding itself; it bans producing “essentially a copy” of a commercially available drug.
- The vitamin B12 question every buyer should ask: After the shortage resolved, many compounders added a second ingredient — most often vitamin B12 (cyanocobalamin or methylcobalamin) — to argue their .
- What this means if you are a patient on it: Possessing and using compounded semaglutide prescribed to you has never been the legal exposure — enforcement targets producers, outsourcing facilitie.
How the shortage exception opened and closed
The legal foundation of the compounded semaglutide boom was drug-shortage law. Semaglutide entered the FDA shortage list in 2022 as demand for Wegovy and Ozempic overwhelmed Novo Nordisk's capacity, and that designation flipped a statutory switch: while a drug is in shortage, 503A pharmacies and 503B outsourcing facilities may compound copies of it without violating the ban on “essentially a copy” products.
On February 21, 2025 the FDA marked the shortage resolved for all doses of injectable semaglutide. Wind-down deadlines followed: 503A pharmacies had to stop copying by April 22, 2025, and 503B facilities by May 22, 2025. The Outsourcing Facilities Association sued to block the delisting, but a federal court in the Northern District of Texas denied a preliminary injunction on April 24, 2025, and the deadlines held. Every compounded semaglutide program operating in mid-2026 therefore rests on something other than the shortage exception.
| Activity | Status | Basis |
|---|---|---|
| Copies during shortage | Ended | Shortage resolved Feb 21, 2025 |
| 503A copies now | Prohibited (deadline Apr 22, 2025) | 'Essentially a copy' bar |
| 503B copies now | Prohibited (deadline May 22, 2025) | Bulks list + shortage both closed |
| 503B bulks pathway | Proposed excluded Apr 30, 2026 | No clinical need; comment to Jun 29, 2026 |
| Patient-specific 503A (documented difference) | Permitted, narrow | Significant-difference determination |
| 4 or fewer 'copy' Rx/month | Enforcement safe harbor | FDA Apr 1, 2026 restatement |
The April 2026 escalation: closing the 503B bulks door
On April 30, 2026 the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the roster of bulk drug substances outsourcing facilities may compound from. The agency's stated basis is that there is no clinical need for outsourcing facilities to make these drugs from bulk API when the approved products are commercially available. A public comment period runs through June 29, 2026 via the federal docket.
Combined with shortage resolution, this proposal closes both legal pathways that allowed industrial-scale compounding. The FDA also made a pointed interpretive move: it explicitly rejected affordability and insurance access as constituting “clinical need.” That single sentence is the ballgame for cheap compounded semaglutide at scale — the primary reason patients chose it is, by the agency's reading, not a lawful reason to compound it.
The narrow paths that survive: 503A and the four-prescription rule
Compounding law never banned compounding itself; it bans producing “essentially a copy” of a commercially available drug. A compounded product is not a copy when a prescriber determines, for an identified individual patient, that a change produces a significant clinical difference — a dose the brand doesn't make, or removal of an ingredient the patient can't tolerate. That determination is patient-specific and must be documented on the prescription.
In an April 1, 2026 clarification, the FDA also restated a limited 503A safe harbor: it does not currently intend to act against a pharmacy that fills four or fewer “essentially a copy” prescriptions of a given preparation per calendar month. That is a genuine but small opening — it accommodates a compounding pharmacy filling an occasional individualized script, not a telehealth platform shipping thousands of identical vials.
The vitamin B12 question every buyer should ask
After the shortage resolved, many compounders added a second ingredient — most often vitamin B12 (cyanocobalamin or methylcobalamin) — to argue their semaglutide was not the same as the approved product. The FDA's April 1, 2026 update used exactly this semaglutide-plus-B12 combination as its example of a product it may still consider “essentially a copy,” depending on route and strength.
The signal to patients is direct: a B12 add-on does not automatically make a compounded semaglutide product lawful, and the agency is skeptical of add-ons that don't produce a genuine, documented clinical difference for the individual. If a program markets “semaglutide + B12” as its whole compliance story, that is a question to ask, not a reassurance to accept.
What this means if you are a patient on it
Possessing and using compounded semaglutide prescribed to you has never been the legal exposure — enforcement targets producers, outsourcing facilities, and prescriber platforms, not patients. Your practical risks are two: supply interruption if your program receives a warning letter or a pharmacy is enjoined, and product quality if your program's compliance posture is thin. Both are testable with three questions.
Ask: what individualized clinical rationale is documented in my file for this specific formulation? Which pharmacy fills it, is it 503A or 503B, and is its license current? And what happens to my supply and records if the program stops operating? A program that answers all three in writing sits in the defensible tier; one that answers none is asking you to carry its regulatory risk at $150 a month.
Where the market goes from here
The compounded GLP-1 market reached roughly 30 percent of U.S. supply at its 2024 peak; the FDA issued more than 50 warning letters to compounders and telehealth distributors during 2025. The direction is unambiguous: the copy-at-scale tier is shrinking under enforcement, and the April 2026 bulks proposal is designed to make it structural rather than temporary.
What survives is a smaller, higher-compliance market: genuine patient-specific 503A compounding, plus the brand and cash-pay alternatives — Wegovy, Ozempic, the Wegovy pill, and manufacturer channels like NovoCare. Read “the FDA banned compounded semaglutide” and “compounding is fully legal” marketing with equal skepticism; both flatten a per-prescription question into a slogan.
Frequently asked questions
Can I get in trouble for using compounded semaglutide?
Enforcement targets producers and platforms, not patients. Your practical risks are supply interruption and product quality, which is why the three verification questions in this article matter more than the headlines.
Does adding B12 make compounded semaglutide legal?
Not by itself. The FDA specifically named semaglutide-plus-B12 as a product it may still treat as 'essentially a copy' absent a documented, individualized clinical difference. Treat a B12 add-on as a marketing point to question, not a compliance guarantee.
Will compounded semaglutide disappear entirely?
The copy-at-scale tier is closing under enforcement and the April 2026 bulks proposal. Genuine patient-specific 503A compounding survives, but it cannot replicate the volume or price of the shortage era.
Sources
- FDA — compounder policy clarification (GLP-1 supply)
- FDA — declaratory order resolving semaglutide shortage
- Pharmacy Times — FDA moves to close 503B bulks door
- Polsinelli — FDA April 1, 2026 compounding clarification
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $119 to $299 a month across the 12 programmes we can price, with a median of $198. The spread between cheapest and dearest is $166 a month, or $1,992 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $119 on its 12-month plan; Oak Longevity follows at $133. Half the market sits below $198 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
2 programmes additionally advertise a semaglutide microdose, the cheapest at $145 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Three questions to ask before acting on semaglutide
The semaglutide figures on this page span $119 to $299 a month across 12 programmes.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
What a longer horizon costs
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What does compounded semaglutide normally cost?
$119 to $299 a month across 12 programmes, with a median of $198. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. 2 programmes advertise a semaglutide microdose, the cheapest at $145 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded semaglutide?
NexLife at $119 a month at a standard therapeutic dose on the 12-month plan ($1,428 total), captured 2026-09-04. 3-month $132; 6-month $125; month-to-month $139. No membership fee, flat at every covered dose. Verified. The next-cheapest is Oak Longevity at $133 (flat, no subscription; not available in California; Provider Reported).